Brief: Rani Therapeutics Announces New Preclinical Pharmacokinetic Data Supporting Transenteric Delivery Of GLP-1 Incretin Triagonist
17/10/2024 13:22
Oct 17 (Reuters) - Rani Therapeutics Holdings Inc
RANI.O :
* RANI THERAPEUTICS ANNOUNCES NEW PRECLINICAL
PHARMACOKINETIC DATA
SUPPORTING TRANSENTERIC DELIVERY OF GLP-1 INCRETIN TRIAGONIST
* RANI THERAPEUTICS HOLDINGS INC - NEW DATA SUPPORTS
RANIPILL
PLATFORM FOR ORAL OBESITY TREATMENTS
* RANI THERAPEUTICS HOLDINGS INC - PHASE 1 STUDY FOR RT-114
EXPECTED TO INITIATE IN 2025
Source text for Eikon: ID:nGNX3G3slK
Further company coverage: RANI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition